Guardant Health (NASDAQ: GH)
Guardant Health Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Guardant Health Company Info
Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.
News & Analysis
Guardant Health: A Promising Player in the Liquid Biopsy Market
Investing in Genetic Testing Stocks
Guardant Health Tops Q4 Revenue Forecast
The oncology testing specialist reported strong top-line growth, but also rising costs and ongoing net losses.
Why Guardant Health Stock Blasted 13% Higher on Thursday
Guardant Delivers Healthy Q3 Growth
The oncology specialist reported stronger third quarter results, powered by strategic product launches and favorable Medicare reimbursement rates.
Why Guardant Health Stock Was the Picture of Health Today
There's nothing like free publicity to help goose the sales of a relatively new product.
Investing in Cancer Stocks
Learn about some of the leading cancer stocks in the U.S stock market this year.
Why Guardant Health Stock Just Crashed 10%
Guardant Health needs cash. Until it can get it from selling enough services, it must sell its own shares instead.
Valuation
Earnings Transcripts
Guardant Health Inc (GH) Q3 2021 Earnings Call Transcript
GH earnings call for the period ending October 30, 2021.
Guardant Health, inc (GH) Q2 2021 Earnings Call Transcript
GH earnings call for the period ending June 30, 2021.
Guardant Health Inc (GH) Q1 2021 Earnings Call Transcript
GH earnings call for the period ending March 31, 2021.
Guardant Health Inc (GH) Q4 2020 Earnings Call Transcript
GH earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.